NCT06628102 Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study
| NCT ID | NCT06628102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | British Columbia Cancer Agency |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,600 participants |
| Start Date | 2023-08-04 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,600 participants in total. It began in 2023-08-04 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this trial is to (a) identify people at high risk of lung cancer who would benefit from LDCT screening but are currently ineligible based on current lung cancer screening criteria (b) provide the framework to manage patients with Incidental Pulmonary Nodules (IPNs) with appropriate follow-up based on accurate interpretation of the Chest CT scan that is already available and (c) develop a simple, point-of-care, minimally invasive test, focusing on the breath and circulating blood proteins, to detect lung cancer, and develop a method to differentiate between cancerous and non-cancerous nodules using a single. Participants will be asked to answer a questionnaire regarding their age, race/ethnicity, smoking history, and residential history if they have ever been told they have chronic obstructive pulmonary disease (COPD), high blood pressure, education level, medications and height and weight. Participants will then be asked to give a breath sample via the breath collection device. All this information will be collected before the breath collection. After that, participants will give 1-2 tablespoons of blood. CT scans with IPN(s) will be reviewed and run through a computer detection software to identify nodules, followed up as per current clinical guidelines.
Eligibility Criteria
Inclusion Criteria: Age 50-80 * Able to consent * Chest CT positive for nodule equal to or greater than 6mm * No additional other cancer- (outside of lung cancer for group 1) * Must be able to abstain from smoking tobacco for 24 hours prior to the breath test. Exclusion Criteria: * Too sick to provide a breath sample * you have smoked in the last 24 hours * You are pregnant * You have been diagnosed with a respiratory infection in the last 3 months * Unwilling to consent to the study
Contact & Investigator
Renelle L Myers, MD
PRINCIPAL INVESTIGATOR
VCH, UBC
Frequently Asked Questions
Who can join the NCT06628102 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06628102 currently recruiting?
Yes, NCT06628102 is actively recruiting participants. Contact the research team at renelle.myers@vch.ca for enrollment information.
Where is the NCT06628102 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06628102 clinical trial?
NCT06628102 is sponsored by British Columbia Cancer Agency. The principal investigator is Renelle L Myers, MD at VCH, UBC. The trial plans to enroll 3,600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.